> the focus has shifted to faster approvals with evidence for new methods and drugs coming down to one high quality trial, and removed stipulations for randomized control trials for ultra rare diseases

Could you share how RFK's policies helped bring this to market faster? (Not challenging you, by the way. Just need help connecting the dots.)